| 10.28 -0.01 (-0.1%) | 03-02 14:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.04  |
1-year : | 12.07 |
| Resists | First : | 10.31 |
Second : | 10.34 |
| Pivot price | 10.3 |
|||
| Supports | First : | 10.27 |
Second : | 8.54 |
| MAs | MA(5) : | 10.29 |
MA(20) : | 10.3 |
| MA(100) : | 10.22 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 38.8 |
D(3) : | 48.1 |
| RSI | RSI(14): 50.6 | |||
| 52-week | High : | 10.5 | Low : | 10.06 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ JENA ] has closed above bottom band by 35.7%. Bollinger Bands are 4.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.33 - 10.39 | 10.39 - 10.45 |
| Low: | 10.11 - 10.19 | 10.19 - 10.26 |
| Close: | 10.18 - 10.29 | 10.29 - 10.39 |
Jena Acquisition Corp. II operates as a blank check company. The company was founded by William P. Foley, II and Richard N. Massey on February 24, 2025 and is headquartered in Las Vegas, NV.
Mon, 12 Jan 2026
Edwards scraps Jenavalve buy in face of FTC objections - bioworld.com
Fri, 09 Jan 2026
Court sides with FTC to put Edwards Lifesciences’ JenaValve acquisition on hold - MassDevice
Tue, 25 Nov 2025
FTC outlines antitrust case against Edwards' $945M JenaValve acquisition - Fierce Biotech
Wed, 27 Aug 2025
Santander’s Wall Street journey takes SPAC detour - TradingView
Wed, 27 Aug 2025
Breakingviews - Santander’s Wall Street journey takes SPAC detour - Reuters
Wed, 20 Aug 2025
FTC challenge to Edwards JenaValve acquisition could delay FDA approval - Cardiovascular Business
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Shell Companies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|